Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06320366 · ClinicalTrials.gov registry record · NA
Testing an Accelerated TMS Protocol for Methamphetamine Use Disorder
A NA study of Methamphetamine Use Disorder, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06320366: Recruiting NA study of Methamphetamine Use Disorder, sponsored by University of Colorado, Denver.
NCT06320366 is a NA study of Methamphetamine Use Disorder that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 20 participants, below the 54-participant average among 12 other Methamphetamine Use Disorder trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06320366, a NA study of Methamphetamine Use Disorder, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators will evaluate the effects of an accelerated Transcranial Magnetic Stimulation (TMS) protocol of the left dorsolateral prefrontal cortex (DLPFC) for moderate to severe methamphetamine use disorder. This is a randomized parallel group design to assess feasibility and safety, evaluate efficacy (use, craving) and identify magnetic resonance imaging (resting state and cue craving) associated with group/outcomes.
Primary Outcome
Proportion completing at least 20 TMS session - sham vs. active
Conditions Studied
Interventions
- DEVICE Sham TMS
- DEVICE Active TMS
Study Locations (1)
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-09-03 |
| Est. Completion | 2028-05-31 |
| Phase | NA |
What NCT06320366 shows while recruiting
NCT06320366 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 54-participant average among 12 other Methamphetamine Use Disorder trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Methamphetamine Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Sham TMS is the first listed.
NCT06320366 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT06320366 about?
NCT06320366 is a clinical study titled "Testing an Accelerated TMS Protocol for Methamphetamine Use Disorder". The investigators will evaluate the effects of an accelerated Transcranial Magnetic Stimulation (TMS) protocol of the left dorsolateral prefrontal cortex (DLPFC) for moderate to severe methamphetamine use disorder. This is a randomized parallel group design to assess feasibility and safety, evaluate...
What is the current status of trial NCT06320366?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2024-09-03. Estimated completion is 2028-05-31.
What conditions does trial NCT06320366 study?
This clinical trial studies the following conditions: Methamphetamine Use Disorder.
What interventions are being tested in trial NCT06320366?
The interventions under investigation include: Sham TMS (DEVICE), Active TMS (DEVICE).
Who is sponsoring clinical trial NCT06320366?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06320366 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Methamphetamine Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06320366's enrollment target sits among peer trials
20 7th of 12 higher than 4 of 12 other Methamphetamine Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Methamphetamine Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Deep TMS of Neural Circuits Associated With Stimulant Use Disorder
RECRUITING · NA
-
Non-Abstinence Outcomes in Methamphetamine Use Disorder
RECRUITING · NA
-
A Pilot Study of Transcranial Magnetic Stimulation Plus Episodic Future Thinking for Methamphetamine Use Disorder
RECRUITING · NA
-
Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV
RECRUITING · Phase 2
-
Methamphetamine and Troriluzole
RECRUITING · Early Phase 1
-
Methamphetamine Cue-reactivity
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI